Cargando…

ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease

Alzheimer’s disease (AD) is an age-related neurodegenerative disease that affects 50 million people worldwide, with 10 million new cases occurring each year. The emotional and economic impacts of AD on patients and families are devastating. Approved treatments confer modest improvement in symptoms,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krafft, Grant A., Jerecic, Jasna, Siemers, Eric, Cline, Erika N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088393/ https://www.ncbi.nlm.nih.gov/pubmed/35557606 http://dx.doi.org/10.3389/fnins.2022.848215

Ejemplares similares

Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics
por: Goure, William F, et al.
Publicado: (2014)

Aβ oligomer induced cognitive impairment and evaluation of ACU193‐MNS‐based MRI in rabbit
por: Rozema, Nicholas B., et al.
Publicado: (2020)

The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
por: Cline, Erika N., et al.
Publicado: (2018)

An acute functional screen identifies an effective antibody targeting amyloid-β oligomers based on calcium imaging
por: Wang, Xueying, et al.
Publicado: (2018)

Amyloid β-protein oligomers and Alzheimer’s disease
por: Hayden, Eric Y, et al.
Publicado: (2013)

β-Amyloid oligomers in aging and Alzheimer’s disease
por: Zahs, Kathleen R., et al.
Publicado: (2013)

Doxycycline for Alzheimer’s Disease: Fighting β-Amyloid Oligomers and Neuroinflammation
por: Balducci, Claudia, et al.
Publicado: (2019)

Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease
por: Mroczko, Barbara, et al.
Publicado: (2018)

The Toxicity of Amyloid β Oligomers
por: Zhao, Li Na, et al.
Publicado: (2012)

Amyloid-β oligomers set fire to inflammasomes and induce Alzheimer's pathology
por: Salminen, Antero, et al.
Publicado: (2008)

Expression of Talaromyces marneffei acuM and acuK Genes in Gluconeogenic Substrates and Various Iron Concentrations
por: Pongpom, Monsicha, et al.
Publicado: (2020)

Postsynaptic Receptors for Amyloid-β Oligomers as Mediators of Neuronal Damage in Alzheimer’s Disease
por: Dinamarca, Margarita C., et al.
Publicado: (2012)

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
por: Hölttä, Mikko, et al.
Publicado: (2013)

Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer’s disease
por: Ferreira, Sergio T., et al.
Publicado: (2015)

Hyperactivity Induced by Soluble Amyloid-β Oligomers in the Early Stages of Alzheimer's Disease
por: Hector, Audrey, et al.
Publicado: (2021)

Breaking the Code of Amyloid-β Oligomers
por: Lesné, Sylvain E.
Publicado: (2013)

The Toxicity and Polymorphism of β-Amyloid Oligomers
por: Huang, Ya-ru, et al.
Publicado: (2020)

Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease
por: Kametani, Fuyuki, et al.
Publicado: (2018)

A Luminex Assay Detects Amyloid β Oligomers in Alzheimer’s Disease Cerebrospinal Fluid
por: Herskovits, Adrianna Z., et al.
Publicado: (2013)

Amyloid-β oligomers unveil a novel primate model of sporadic Alzheimer's disease
por: Jebelli, Joseph D., et al.
Publicado: (2015)

Stabilization of a Membrane-Associated Amyloid-β Oligomer for Its Validation in Alzheimer's Disease
por: Serra-Batiste, Montserrat, et al.
Publicado: (2018)

Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid
por: Yang, Ting, et al.
Publicado: (2019)

The Therapeutic and Diagnostic Potential of Amyloid β Oligomers Selective Antibodies to Treat Alzheimer’s Disease
por: Viola, Kirsten L., et al.
Publicado: (2022)

Oligomer Formation by Amyloid-β42 in a Membrane-Mimicking Environment in Alzheimer’s Disease
por: Rosenberry, Terrone L., et al.
Publicado: (2022)

Characterization of a Novel Mouse Model of Alzheimer’s Disease—Amyloid Pathology and Unique β-Amyloid Oligomer Profile
por: Liu, Peng, et al.
Publicado: (2015)

The biogenesis and biology of amyloid β oligomers in the brain
por: Ashe, Karen Hsiao
Publicado: (2020)

A highly sensitive novel immunoassay specifically detects low levels of soluble Aβ oligomers in human cerebrospinal fluid
por: Yang, Ting, et al.
Publicado: (2015)

Alzheimer’s Toxic Amyloid Beta Oligomers: Unwelcome Visitors to the Na/K ATPase alpha3 Docking Station
por: DiChiara, Thomas, et al.
Publicado: (2017)

Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
por: Fedele, Ernesto
Publicado: (2023)

Alzheimer Aβ peptide interactions with lipid membranes: Fibrils, oligomers and polymorphic amyloid channels
por: Tofoleanu, Florentina, et al.
Publicado: (2012)

Synthetic amyloid-β oligomers drive early pathological progression of Alzheimer’s disease in nonhuman primates
por: Yue, Feng, et al.
Publicado: (2021)

Poised to migrate
por: Wells, William A.
Publicado: (2003)

The Poise of Scholarship
por: Hopkins, Henry Reed
Publicado: (1909)

Editorial: Beta-Amyloid oligomer specific treatments for Alzheimer's disease
por: Hillen, Heinz
Publicado: (2023)

SAT-193 Evaluating Levels of Luteinizing Hormone Receptor Dimers and Larger Oligomers
por: Althumairy, Duaa
Publicado: (2019)

Can an Infection Hypothesis Explain the Beta Amyloid Hypothesis of Alzheimer’s Disease?
por: Fulop, Tamas, et al.
Publicado: (2018)

The amyloid hypothesis of Alzheimer's disease at 25 years
por: Selkoe, Dennis J, et al.
Publicado: (2016)

Is there a sodium effect in fibrillar amyloid-β oligomers?
por: Horn, Anselm HC, et al.
Publicado: (2014)

Polymorphism of Oligomers of a Peptide from β-Amyloid
por: Pham, Johnny D., et al.
Publicado: (2014)

The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy
por: Sengupta, Urmi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rq9aglhhhbtr8m38f8edo8nldq